Identification
- Generic Name
- L-Saccharopine
- DrugBank Accession Number
- DB04207
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for L-Saccharopine (DB04207)
- Weight
- Average: 276.2863
Monoisotopic: 276.132136382 - Chemical Formula
- C11H20N2O6
- Synonyms
- epsilon-N-(L-Glutar-2-yl)-L-lysine
- N-[(S)-5-Amino-5-carboxypentyl]-L-glutamic acid
- N6-(L-1,3-Dicarboxypropyl)-L-lysine
- Saccharopine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UAlpha-aminoadipic semialdehyde synthase, mitochondrial Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category 2-Aminoadipic 2-Oxoadipic Aciduria Disease Glutaric Aciduria Type I Disease Saccharopinuria/Hyperlysinemia II Disease Hyperlysinemia I, Familial Disease Lysine Degradation Metabolic Hyperlysinemia II or Saccharopinuria Disease Pyridoxine Dependency with Seizures Disease - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Glutamic acid and derivatives
- Alternative Parents
- L-alpha-amino acids / Tricarboxylic acids and derivatives / Amino fatty acids / Amino acids / Dialkylamines / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives show 1 more
- Substituents
- Aliphatic acyclic compound / Alpha-amino acid / Amine / Amino acid / Amino fatty acid / Carbonyl group / Carboxylic acid / Fatty acyl / Glutamic acid or derivatives / Hydrocarbon derivative show 12 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- L-lysine derivative, amino acid opine (CHEBI:16927)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- WBQ73O8W32
- CAS number
- 997-68-2
- InChI Key
- ZDGJAHTZVHVLOT-YUMQZZPRSA-N
- InChI
- InChI=1S/C11H20N2O6/c12-7(10(16)17)3-1-2-6-13-8(11(18)19)4-5-9(14)15/h7-8,13H,1-6,12H2,(H,14,15)(H,16,17)(H,18,19)/t7-,8-/m0/s1
- IUPAC Name
- (2S)-2-{[(5S)-5-amino-5-carboxypentyl]amino}pentanedioic acid
- SMILES
- N[C@@H](CCCCN[C@@H](CCC(O)=O)C(O)=O)C(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000279
- KEGG Compound
- C00449
- PubChem Compound
- 160556
- PubChem Substance
- 46505056
- ChemSpider
- 141086
- ChEBI
- 16927
- ZINC
- ZINC000001532666
- PDBe Ligand
- SHR
- Wikipedia
- Saccharopine
- PDB Entries
- 1e5q / 3uh1
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 5.25 mg/mL ALOGPS logP -2.8 ALOGPS logP -5.4 Chemaxon logS -1.7 ALOGPS pKa (Strongest Acidic) 1.44 Chemaxon pKa (Strongest Basic) 10.89 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 149.95 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 63.95 m3·mol-1 Chemaxon Polarizability 28.14 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.5377 Blood Brain Barrier - 0.5113 Caco-2 permeable - 0.8478 P-glycoprotein substrate Non-substrate 0.5568 P-glycoprotein inhibitor I Non-inhibitor 0.9719 P-glycoprotein inhibitor II Non-inhibitor 0.9732 Renal organic cation transporter Non-inhibitor 0.9101 CYP450 2C9 substrate Non-substrate 0.8747 CYP450 2D6 substrate Non-substrate 0.8217 CYP450 3A4 substrate Non-substrate 0.7953 CYP450 1A2 substrate Non-inhibitor 0.92 CYP450 2C9 inhibitor Non-inhibitor 0.9603 CYP450 2D6 inhibitor Non-inhibitor 0.9586 CYP450 2C19 inhibitor Non-inhibitor 0.9649 CYP450 3A4 inhibitor Non-inhibitor 0.9169 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9974 Ames test Non AMES toxic 0.7985 Carcinogenicity Non-carcinogens 0.9125 Biodegradation Ready biodegradable 0.8264 Rat acute toxicity 1.1770 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9593 hERG inhibition (predictor II) Non-inhibitor 0.9522
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 177.4797012 predictedDarkChem Lite v0.1.0 [M-H]- 177.2824012 predictedDarkChem Lite v0.1.0 [M-H]- 177.7079012 predictedDarkChem Lite v0.1.0 [M-H]- 161.22371 predictedDeepCCS 1.0 (2019) [M+H]+ 176.2376012 predictedDarkChem Lite v0.1.0 [M+H]+ 160.4890336 predictedDarkChem Standard v0.1.0 [M+H]+ 176.3629012 predictedDarkChem Lite v0.1.0 [M+H]+ 163.58171 predictedDeepCCS 1.0 (2019) [M+Na]+ 176.4848012 predictedDarkChem Lite v0.1.0 [M+Na]+ 176.7364012 predictedDarkChem Lite v0.1.0 [M+Na]+ 176.1849012 predictedDarkChem Lite v0.1.0 [M+Na]+ 169.67485 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Saccharopine dehydrogenase (nadp+, l-lysine-forming) activity
- Specific Function
- Bifunctional enzyme that catalyzes the first two steps in lysine degradation. The N-terminal and the C-terminal contain lysine-ketoglutarate reductase and saccharopine dehydrogenase activity, respe...
- Gene Name
- AASS
- Uniprot ID
- Q9UDR5
- Uniprot Name
- Alpha-aminoadipic semialdehyde synthase, mitochondrial
- Molecular Weight
- 102130.895 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52